A quantum leap in cancer vaccines? by Eli Gilboa
COMMENTARY Open Access
A quantum leap in cancer vaccines?
Eli Gilboa
Vaccination, namely the controlled activation of antigen-
specific immune cells, is a first and critical step toward en-
gendering protective immunity against cancer. A large
number of vaccination strategies developed to date, from
simple to complex, have shown but limited efficacy. In a re-
cent article in Nature, Kranz and colleagues describe what
appears to be a remarkably effective and relatively simple
approach, using tumor antigen encoding mRNA complexed
to cationic lipid carriers, RNA-lipoplexes (RNA-LPXs) like
DOTMA, DOPE and DOTAP [1]. Vaccination with such
mRNA-lipid complexes, exhibiting a net positive charge
that was shown to improve mRNA delivery in vitro, have
been previously used but were not particularly effective in
murine tumor immunotherapy studies. What was different
here? Amazingly and counter intuitively, all it took was to
tweak the net charge of the RNA to lipid ratio to be slightly
negative. This is not to take away from the thorough and
extensive study and the foresight of the investigators that
led to this discovery. Flies in the face of the common
wisdom that therapeutic advances in cancer will require
complex and elaborate protocols such as patient-specific ex
vivo generated dendritic cells based vaccines.
The main finding was that the intravenously injected
negatively charged anionic, but not the conventional neutral
or positively charged cationic mRNA lipoplexes were taken
up almost exclusively by CD11c +macrophages and den-
dritic cells (DC) residing in the spleen, lymph nodes and
other organs like the liver. This was accompanied by excep-
tionally strong and durable T cell responses unlike what has
been previously seen. The mechanism was dependent on
macropinocytosis-mediated uptake of the RNA-encoded
antigens by the DC. Macropinocytosis, which is constitu-
tively active in immature DC and downregulated upon their
maturation, is unique in its ability to efficiently promote the
translocation of its cargo to the cytoplasm, and plays a key
role in cross-presentation of exogenous class II, and prob-
ably class I, antigens. Uptate of the RNA-LPXs by the DC
led to a TLR7 dependent induction of IFNα presumably
triggered by the encapsulated mRNA, which led to their
maturation and ability to optimally activate T cells. Local
and transient expression of IFNα is a key mediator
promoting the induction of potent T cell immunity against
blood-borne pathogens [2] and tumors [3]. At about the
same time, Broos and colleagues have published a study that
parallels the findings in this paper using a commercially
available lipid formulation, Lipofectamine RNAiMAX,
showing that the encapsulated mRNA in the negatively
charged RNA-lipoplexes is targeted to phagocytic cells in
the spleen and liver, translated mainly in CD11c+ DC,
induces IFNα, and stimulates a T cell response [4].
This rather simple and cost-effective vaccination
protocol using readily available reagents offers a number
of important advantages: (i) It dispenses with the need
to develop and use a targeting ligands to suitable recep-
tors like DEC205 or Clec9A that are expressed on the
surface of resident DC [5]. (ii) Delivering antigens to DC
in situ by conjugation of the antigen to targeting ligands
can stimulate potent immunity but requires the use of
adjuvants to activate the targeted DC such as anti-CD40
antibodies administered systemically [5]. The RNA-LPX
provides its own adjuvant, the mRNA itself, to locally
and transiently induces IFNα. (iii) Direct injection of
antigen encoding mRNA, not DNA, is a surprisingly ef-
fective and straightforward approach to induce (tumor)
immunity in vivo [6]. (iv). Encapsulation of the mRNA
into the lipoplexes protects the unmodified mRNA from
nuclease degradation. (v). Lastly, the nanoparticle size
RNA-LPXs are efficiently and preferentially taken up by
phagocytic cells including dendritic cells.
Ultimately the question is whether the RNA-LPX vac-
cine will elicit clinical responses in cancer patients that are
superior to what we have seen so far. In transplantable
murine tumor models vaccination in prophylactic and
therapeutic settings suggests that the approach has merit,
but the conditions were not particularly stringent so the
potency was difficult to asses. More impressive were early
results from an ongoing clinical trial in melanoma pa-
tients. Three patients treated with low to moderate doses
of the RNA-LPX vaccine targeting 4 melanoma antigens
exhibited robust and durable T cell responses, in one pa-
tients reaching levels comparable to that of CMV and
EBV T cell responses that are thought to be protective.
Such responses appear to be more robust than what has
been generally seen in similar settings but it is hard toCorrespondence: egilboa@med.miami.edu
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judge. Evaluation of more patients, treated with higher
doses of vaccine, and signs of clinical responses, are
eagerly awaited.
It is prudent to assume that the RNA-LPX vaccination as
a stand alone therapy will not be the sought for “magic bul-
let”, but rather an important component in a multi-
pronged approach. One challenge is to improve the vaccine
induced immune response, expanding the vaccine activated
T cells thru 4-1BB, OX40, GITR or CD27 costimulation,
and extending its persistence by skewing the differentiation
of the vaccine-activated T cells to become long lasting
memory cells [7], especially (tumor) resident memory T
cells [8]. Not less and probably more important will be to
enhance the susceptibility of the patients’ disseminated
tumor lesions to the vaccine generated T cells, countering
immune resistance (not limited to checkpoint blockade),
and overcoming tumor induced barriers that prevent T
cells and antigen presenting cells from penetrating into the
tumor mass [9].
Initial evidence from the murine studies and the on-
going clinical trial is that the RNA-LPX vaccine will be
safe. There may be some risk that the systemically admin-
istered RNA-LPX could elicit excessively high levels of
IFNα by the CD11c + cells scattered throughout the body
that could provoke autoimmune sequalae especially in
predisposed individuals. This can be minimized by target-
ing the RNA lipoplexes to the tumor lesions using suitable
ligands decorating the lipoplexes that bind to tumor se-
creted products such as VEGF or osteopontin [10]. Tumor
targeting may be worth considering also in combination
with systemic delivery to enhance the immunogenicity of
tumor lesions. This is based on studies showing that intra-
tumoral administration of STING ligands can elicit tumor
immunity via local induction of IFNα [11]. Targeting the
RNA lipoplexes to tumor lesions, in addition to systemic
delivery, could serve a similar purpose.
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